The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)

The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)